Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020
October 21, 2020 08:00 ET
|
Vir Biotechnology, Inc.
– Preclinical data show VIR-2482 has broad neutralizing potential against all major strains of influenza A from the last 100 years – – Extended half-life observed in Phase 1 demonstrates potential...
Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
September 24, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019 Oxford, UK, and Cambridge, MA, US,...
Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week 2018
September 26, 2018 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week...
Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017
October 09, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Oct. 09, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
T2 Biosystems Announces Presentations at IDWeek 2016
October 13, 2016 08:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced the Company’s...